Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash & Equivalents (2023 - 2025)

Zenas BioPharma has reported Cash & Equivalents over the past 3 years, most recently at $110.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $110.6 million for Q4 2025, down 65.4% from a year ago — trailing twelve months through Dec 2025 was $110.6 million (down 65.4% YoY), and the annual figure for FY2025 was $110.6 million, down 65.4%.
  • Cash & Equivalents for Q4 2025 was $110.6 million at Zenas BioPharma, down from $115.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ZBIO hit a ceiling of $360.0 million in Q3 2024 and a floor of $37.2 million in Q1 2024.
  • Median Cash & Equivalents over the past 3 years was $113.1 million (2025), compared with a mean of $161.4 million.
  • Peak annual rise in Cash & Equivalents hit 745.67% in 2025, while the deepest fall reached 76.07% in 2025.
  • Zenas BioPharma's Cash & Equivalents stood at $56.9 million in 2023, then surged by 462.36% to $319.7 million in 2024, then crashed by 65.4% to $110.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $110.6 million (Q4 2025), $115.6 million (Q3 2025), and $44.0 million (Q2 2025) per Business Quant data.